CNS Pharma (NASDAQ:CNSP) Stock, Quote.Headers.trade-ideas

CNS Pharmaceuticals

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGRI

ATNM

ATPC

BJDX

CHGG

CNSP

HPAI

LCID

LUMN

PLTR

RXST

SERV

SMFG

SPWR

TENK

TPET

UPXI

Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket

Kellanova

AIXI

APLD

AQMS

CIFR

CLSK

FFIN

INDO

IREN

MGOL

MIRA

MSTR

RSKD

WULF

XXII

ZVRA

Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Headquarters_Rahway-Site-Entrance_HI

Intraday Update

AMKR

BIMI

BLMZ

CALC

CLDX

CRWD

CVLT

EKSO

ENVB

FFIV

HAYW

HLIT

IMNN

INVO

ISPO

JBLU

JTAI

LSCC

MBIN

NIPG

NVAX

ONEW

PCSA

PHAR

PYPL

RGEN

RMBS

SMRT

TLRY

TRNS

TWOU

VBIV

VRNS

VSEE

Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

CNS Pharmaceuticals Inc

In the latest development, Taiwan has strongly denied China&#8217;s accusations of Taiwanese-backed cyberattacks, calling them baseless and part of a disinformation campaign.
What Happened: Taiwan&#8217;s government officials have dismissed China&#8217;s accusations of Taiwanese hacking as false on Tuesday, Reuters reported on Tuesday. Beijing had claimed a Taiwan military-backed group named &#8220;Anonymous64&#8221; was responsible for cyberattacks on Chinese targets.
China&#8217;s national security ministry made these allegations on Monday, urging citizens to report &#8220;anti-propaganda sabotage&#8221; and even published photos of three Taiwanese individuals they claimed were involved. Taiwan&#8217;s Defence Minister Wellington Koo responded by asserting that China is the primary source of global cyberattacks, targeting Taiwan and other democracies.
&#8220;China is the first country when it comes to daily cyber attacks, doing it against Taiwan and countries with similar democratic ideals. They are the real originators,&#8221; Koo stated. 
He further emphasized that China&#8217;s accusations are baseless and will not deter Taiwan&#8217;s military from its duties.
Premier Cho Jung-tai also addressed the issue, accusing China of spreading disinformation to undermine Taiwan. 
&#8220;We must respond forcefully to fake news accusations against us,&#8221; Cho said. Taiwan continues to reject China&#8217;s sovereignty claims, maintaining that only its people can determine the island&#8217;s future.
See Also: <a href="https://www.benzinga.com/news/24/09/40980997/china-tightens-export-rules-on-nuclear-biotech-and-missile-technologies-to-bolster-national-security?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">China Tightens Export Rules On Nuclear, Biotech And Missile Technologies To Bolster National Security Amid Global Tensions</a>
Why It Matters: The allegations from China come amid escalating tensions between the two nations. On Monday, Beijing&#8217;s top intelligence agency accused a<a href="https://www.benzinga.com/news/24/09/40978209/china-accuses-taiwan-backed-hacker-group-of-targeting-beijing-amid-deteriorating-cross-strait-relati"> group of Taiwanese hackers</a>, allegedly backed by Taipei&#8217;s defense ministry, of targeting websites in mainland China, Hong Kong, and Macau. The group, known as "Anonymous64," is described as a "cyber army" supported by Taiwan's Information, Communications and Electronic Force Command (ICEFCOM). These accusations were made as cross-strait relations continued to deteriorate, especially after Lai Ching-te assumed leadership in Taiwan in May. Lai is a member of the Democratic Progressive Party (DPP), which leans towards independence, a stance that Beijing strongly opposes.
Additionally, the U.S. and Taiwan have been strengthening their <a href="https://www.benzinga.com/news/24/09/40957200/amid-china-threat-us-and-taiwan-team-up-to-boost-drone-industry-cooperation-to-de-risk-supply-chains">cooperation to counteract</a> Chinese influence. In September, a delegation of U.S. drone and anti-drone companies visited Taipei to discuss creating supply chains independent of China. This collaboration aims to mitigate risks associated with Chinese products that have dual civilian and military uses. Taiwan&#8217;s Defence Minister Wellington Koo stated that this visit is an opportunity for Taiwan to integrate into U.S. supply chains and engage in co-production, helping Taiwan overcome export challenges due to its international status and pressure from China.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Politics

Global

General

Taiwan Claps Back After China Blames Taipei Backed Hackers For Cyberattacks: 'They Are The Real Originators'

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Monday.
U.S. stocks settled higher on Monday, with the S&amp;P 500 jumping to a new closing high.
All three major indices recorded weekly gains, with the S&amp;P 500 gaining around 1.4% and adding more than 19% in 2024. The Dow gained around 1.6% last week, while the tech-heavy Nasdaq jumped around 1.5% during the week.
On the economic data front, the S&amp;P Global manufacturing PMI declined to 47 in September from 47.9 in the prior month, versus market estimates of 48.5. The S&amp;P Global flash composite PMI slipped to 54.4 in September compared to 54.6 in August and versus market estimates of 54.3.
Most sectors on the S&amp;P 500 closed on a positive note, with energy, consumer discretionary, and real estate stocks recording the biggest gains on Monday. However, healthcare and communication services stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 61 points to 42,124.65 on Monday. The S&amp;P 500 rose 0.28% to 5,718.57, while the Nasdaq Composite gained 0.14% at 17,974.27 during Monday's session.
Investors are awaiting earnings results from AAR Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) and Red Cat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 64.4, the index remained in the &#8220;Greed&#8221; zone on Monday, versus a prior reading of 63.9.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40980672/top-3-financials-stocks-that-may-plunge-in-september">Top 3 Financials Stocks That May Plunge In September</a></li>
</ul>

Earnings

Long Ideas

RCAT

S&P Settles At Fresh Record High: Investor Sentiment Improves, But Fear Index Remains In 'Greed' Zone

South Korea has issued a stern warning of military action in response to Kim Jong Un&#8216;s North Korea recently launching trash-filled balloons.
What Happened: Incheon International Airport, one of Asia&#8217;s busiest, faced temporary shutdowns after a balloon was spotted nearby. Operations paused for 70 minutes before the balloon landed in the ocean. Shortly after resuming, debris was found, causing another brief halt, South China Morning Post <a href="https://scmp.com/week-asia/politics/article/3279661/south-korea-vows-military-response-norths-balloons-stoking-escalation-fears?module=top_story&amp;pgtype=homepage">reported</a> on Tuesday.
North Korean balloons have disrupted operations at Incheon and Gimpo airports five times in June and July, impacting 133 flights and 18,000 passengers, according to Seoul aviation authorities.
Since late May, North Korea has launched around 5,500 trash-filled balloons on 22 occasions, retaliating against anti-Pyongyang leaflets sent by South Korean defectors and activists. This month alone, 11 launches occurred, including about 120 balloons from Sunday evening to Monday morning.
South Korea&#8217;s Joint Chiefs of Staff condemned the North&#8217;s actions, stating that &#8220;stern military measures&#8221; would be taken if public safety is threatened. In response, South Korea resumed propaganda broadcasts along the border, which North Korea countered with its own broadcasts.
See Also: <a href="https://www.benzinga.com/news/24/09/40973164/nba-star-shaquille-oneal-threw-tim-walz-out-from-his-big-chicken-restaurant-and-said-dont-come-back?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">NBA Star Shaquille O&#8217;Neal Threw Tim Walz Out From His Big Chicken Restaurant And Said, &#8216;Don&#8217;t Come Back&#8217;</a>
Lee Il-woo from the Korea Defence Network suggested that South Korea could use small-caliber machine guns on helicopters to shoot down the balloons. Meanwhile, Shin Won-sik, South Korea&#8217;s top security official, warned that North Korea might escalate tensions further with a nuclear test.
Why It Matters: The balloon incidents have been escalating <a href="https://www.benzinga.com/news/24/05/39058090/south-korea-accuses-kim-jong-uns-north-korea-of-sending-balloons-filled-with-trash-and-excrement">since late May,</a> when South Korea accused North Korea of sending balloons filled with trash and excrement over the fortified border. The South Korean military had to deploy its explosives ordnance unit and chemical and biological warfare response team to inspect and collect the objects, urging residents to avoid and report any sightings.
In early June, North Korean defectors in Seoul retaliated by <a href="https://www.benzinga.com/news/24/06/39206733/after-kim-jong-un-pauses-trash-filled-balloons-north-korean-defectors-float-k-pop-balloons-over-bord">launching large balloons</a> filled with K-pop and South Korean cultural content across the border. This act was justified as a response to the trash-filled balloons sent by North Korea, which they considered an insult to the South Korean people.
Most recently, in late July, North Korea launched nearly <a href="https://www.benzinga.com/news/24/07/39950625/kim-jong-uns-north-korea-sent-nearly-500-trash-balloons-to-south-korea-in-last-24-hours-disrupting-f">500 trash-filled balloons</a> into South Korean airspace within a 24-hour period, causing flight disruptions and even a rooftop fire. This ongoing propaganda campaign by North Korea against defectors and activists in South Korea has led to multiple disruptions at Seoul's Gimpo and Incheon airports.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Image by Kanchi1979 via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

South Korea Vows 'Stern Military Action' After Trash Balloons From Kim Jong Un's North Korea Disrupt Country's Busiest Airport

Takeda ((<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&amp;,%20esheet=54124287&amp;,%20newsitemid=20240918509211&amp;,%20lan=en-US&amp;,%20anchor=TSE%3A4502%2FNYSE%3ATAK&amp;,%20index=1&amp;,%20NYSE:%3Ca%20class=">TAK</a>) today announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA Capsules 1mg/5mg (generic name: fruquintinib), a selective oral inhibitor of vascular endothelial growth factor receptor (VEGFR) -1, -2 and -3, for the treatment of advanced or recurrent colorectal cancer (CRC) that is neither curable nor resectable and that has progressed after chemotherapy.
The approval is based primarily on the results of the FRESCO-2 trial, a global Phase 3 clinical trial conducted in the United States, Europe, Japan and Australia. The trial compared FRUZAQLA plus best supportive care (BSC) with placebo plus BSC in patients with previously treated metastatic colorectal cancer (mCRC). The FRESCO-2 trial met all primary and key secondary efficacy endpoints and demonstrated consistent benefits in patients who received FRUZAQLA, regardless of the types of therapy the patients had previously received. FRUZAQLA demonstrated a manageable safety profile in the FRESCO-2 trial, with the incidence of adverse events leading to discontinuation being 21% in the placebo plus BSC arm compared to 20% in the FRUZAQLA plus BSC arm.1 The data from the FRESCO-2 trial were <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%252823%252900772-9%2Fabstract&amp;esheet=54124287&amp;newsitemid=20240918509211&amp;lan=en-US&amp;anchor=published&amp;index=2&amp;md5=4ae4f0cb6c84175356b3a0226e262316">published</a> in The Lancet in June 2023.
Dr. Takayuki Yoshino, deputy director of hospital, head, Division for the Promotion of Drug and Diagnostic Development, and chief, Department of Gastrointestinal Oncology at the National Cancer Center Hospital East, who served on the FRESCO-2 study Steering Committee, said, "Although the mortality rate of colorectal cancer has been going down in recent years due to early screening and advances in treatment, the 5-year survival rate for metastatic colorectal cancer remains low and new treatment options are much in need. The approval of FRUZAQLA in Japan offers new hope for patients and families of patients with metastatic colorectal cancer, as well as for healthcare personnel involved in colorectal cancer treatment. I feel that it is of great clinical significance."
"For more than a decade, Takeda has been a leader in advancing the treatment of metastatic colorectal cancer in Japan. With this approval of FRUZAQLA, we are able to further support patients living with this debilitating disease," said Teresa Bitetti, president of the Global Oncology Business Unit at Takeda. "FRUZAQLA is now approved in the U.S., European Union, Japan and a number of other countries around the world, and we remain committed to bringing this treatment to additional patients with metastatic colorectal cancer around the world who urgently need new therapeutic options."

Government

Regulations

Takeda's FRUZAQLA Capsules Approved in Japan for Advanced Colorectal Cancer Treatment

Oportun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRT#NASDAQ">OPRT</a>), a mission-driven financial services company, today announced the closing of an amendment and extension to its long-term warehouse facility. Features of this facility include: &nbsp;
<ul>
<li>$306 million total commitment</li>
<li>Goldman Sachs as senior lender – and Jefferies, as mezzanine lender – both existing, longstanding lenders to Oportun</li>
<li>A new two-year revolving period</li>
<li>Collateralized by Oportun's unsecured and secured personal loan originations &nbsp;</li>
</ul>
"This warehouse facility extension expands on Oportun's longstanding lending relationships", said Jonathan Coblentz, Chief Financial Officer of Oportun. "With the support of our lenders at Goldman Sachs and Jefferies, this committed financing will help drive Oportun's responsible growth in the years ahead."
Oportun maintains a diverse set of capital sources including committed warehouse facilities, asset-backed securitizations, corporate-level debt financing, and whole loan sales.

OPRT

Reported Earlier, Oportun Secures $306M Financing Extension With Goldman Sachs and Jefferies

With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects AutoZone, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) to report quarterly earnings at $53.53 per share on revenue of $6.22 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. AutoZone shares fell 0.7% to $3,027 in after-hours trading.</li>
<li>AAR Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) posted better-than-expected results for its first quarter on Monday. The company reported quarterly earnings of 85 cents which beat the analyst consensus estimate of 82 cents per share. AAR shares gained 3.4% to $71.44 in the after-hours trading session.</li>
<li>Analysts expect THOR Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) to post quarterly earnings at $1.30 per share on revenue of $2.47 million before the opening bell. THOR Industries shares gained 1.6% to $104.83 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) announced a $2 billion private placement of senior convertible notes. Snowflake shares fell 3.1% to $109.71 in the after-hours trading session.</li>
<li>Analysts are expecting KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) to post quarterly earnings at $2.06 per share on revenue of $1.73 billion. The company will release earnings after the closing bell. KB Home shares gained 1.1% to close at $88.20 on Monday.</li>
</ul>
Check This Out:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40980672/top-3-financials-stocks-that-may-plunge-in-september">Top 3 Financial Stocks That May Plunge In September</a></li>
</ul>
Photo courtesy: Shutterstock

SNOW

AutoZone, Thor Industries And 3 Stocks To Watch Heading Into Tuesday

Excelerate Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EE#NYSE">EE</a>) (the "Company" or "Excelerate"), a leading provider of floating storage and regasification units (FSRUs) and liquefied natural gas (LNG) solutions, and PetroVietnam Technical Services Corporation (PTSC), a subsidiary of Vietnam Oil and Gas Group (PetroVietnam) and the leading provider of oil &amp; gas and industrial services in Vietnam, have signed a strategic partnership agreement to jointly study FSRU based technical solutions for LNG imports into Vietnam.
Through this strategic alliance, Excelerate and PTSC will leverage their unique strengths and combined resources to deliver affordable and reliable energy solutions that address Vietnam's growing energy demands while supporting the country's transition to carbon neutrality.
Under the partnership agreement, the two companies will conduct joint feasibility studies to assess the viability of FSRU opportunities in Vietnam. The studies aim to optimize existing natural gas infrastructure and augment domestic supply with regasified LNG to help meet the growing demand for natural gas and stimulate the development of a regional gas market.

Reported Earlier, Excelerate Energy and PetroVietnam Partner To Boost Vietnam's LNG Imports

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.firstam.com&amp;esheet=54126266&amp;newsitemid=20240923810819&amp;lan=en-US&amp;anchor=First+American+Financial+Corporation&amp;index=1&amp;md5=70ff5a7d15f2af52f7e408adc440e753">First American Financial Corporation</a> (NYSE: <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.firstam.com%2Finvestor&amp;esheet=54126266&amp;newsitemid=20240923810819&amp;lan=en-US&amp;anchor=FAF&amp;index=2&amp;md5=42d3b12043586201743f4291dde8c059">FAF</a>), a premier provider of title, settlement and risk solutions for real estate transactions, today announced the pricing of a public offering of $450 million of its 5.450 percent senior notes due 2034. The offering is expected to close on September 30, 2024, subject to customary conditions.
The notes will be general senior unsecured obligations of the company and will rank equally in right of payment with the company's existing and future senior unsecured indebtedness. Interest will be paid semi-annually on March 30 and September 30, beginning March 30, 2025. The company intends to use the net proceeds from the sale of the notes for repayment at maturity of the company's 4.60% senior notes due 2024 and for general corporate purposes, which may include, among other possible uses, acquisitions, funding for working capital, repurchase of the company's capital stock and other capital expenditures. The company may also use the net proceeds for temporary investments until it needs them for general corporate purposes.

Offerings

Reported Earlier, First American Financial Raised $450M Via Senior Notes Offering For Debt Repayment

Bank of America has identified crucial dates for the stock market leading up to the <a href="https://www.benzinga.com/markets/equities/24/09/40974512/stifel-warns-of-12-market-drop-by-end-of-2024-as-s-p-500-faces-high-valuations-and-speculative-r">November Presidential election</a>.
What Happened: In a note released on Monday, Bank of America highlighted several key dates. The bank used options prices to predict potential movements in the S&amp;P 500 index. The most significant date is Nov. 6, the day after the election, with an estimated 2.5% move in either direction, <a href="https://markets.businessinsider.com/news/stocks/stock-market-most-important-daysstock-market-between-now-and-election-2024-9">reported</a> Business Insider.
Other important dates include Oct. 4 and Nov. 1, when nonfarm payroll reports are released. These dates could see a 1% move in the S&amp;P 500. Oct. 21 is another critical date, marking the start of major tech companies&#8217; third-quarter earnings announcements.
Additionally, Oct. 10 is noted for the release of the September CPI data, though its impact is expected to be less significant compared to labor market data. The Federal Reserve&#8217;s recent interest rate cut has shifted focus from inflation to labor market indicators.
See Also: <a href="https://www.benzinga.com/news/24/09/40972893/trumps-mars-landing-promise-gets-slammed-by-peter-schiff-even-as-elon-musk-says-spacex-plans-5-launc?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Mars Landing Promise Gets Slammed By Peter Schiff Even As Elon Musk Says SpaceX Plans 5 Launches To Red Planet In 2 Years</a>
Why It Matters: The stock market is on edge as it approaches the November election, with several analysts predicting significant volatility. 
Stifel recently warned of a <a href="https://www.benzinga.com/markets/equities/24/09/40974512/stifel-warns-of-12-market-drop-by-end-of-2024-as-s-p-500-faces-high-valuations-and-speculative-r">potential 12% market drop by the end of 2024</a>, citing high valuations and speculative risks. Chief equity strategist Barry Bannister pointed out that the S&amp;P 500 could experience a correction to the low 5,000s by the fourth quarter.
In early September, Tom Lee, a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40701071/market-bull-warns-of-up-to-10-september-pullback-urges-caution-but-stresses-be-read">prominent equity strategist</a>, anticipated a 7%-10% market pullback, urging caution but also advising investors to be ready to &#8220;buy that dip.&#8221; Lee noted that September has historically been the weakest month for stocks, with the S&amp;P 500 averaging a 0.7% loss every September since 1950.
Additionally, market strategist Jay Woods discussed the potential impacts of the election year and Federal Reserve rate cuts on the stock market. In an interview, Woods mentioned that the Fed&#8217;s expected rate cut in September comes as investors try to predict market movements <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/08/40533318/exclusive-market-strategist-on-small-cap-rally-election-year-fed-cuts-and-whats-next-i">amid the 2024 presidential election</a>. Woods says the Fed was late to raise rates and has been late to cut rates.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40969619/trump-ally-sarah-huckabee-sanders-jabs-kamala-harris-for-not-having-biological-children-doesnt-have?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Ally Sarah Huckabee Sanders Jabs Kamala Harris For Not Having Biological Children: &#8220;Doesn&#8217;t Have Anything Keeping Her Humble!&#8221;</a></li>
</ul>
Image Via Shutterstock 
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Equities

Key Stock Market Dates Predicting Major Swings Revealed Ahead Of 2024 Election, According To Bank Of America

Nova Minerals Limited ("Nova" and the "Company") (Nasdaq NVA, NVAWW) (ASX: NVA), (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NVAAF#OTC">NVAAF</a>)(FSE: QM3)), a gold and critical minerals exploration stage company focused on advancing the Estelle Gold Project in Alaska, U.S.A., today announced the pricing of an underwritten public offering of 430,000 American Depository Shares ("ADS"), with an ADS-to-ordinary-share ratio of 1 to 60, at a price to the public of $5.00 per ADS, for gross proceeds of $2,150,000, before deducting underwriting discounts and offering expenses. In addition, Nova has granted the underwriters a 45-day option to purchase up to an additional 43,000 ADSs to cover over-allotments, if any. &nbsp;
The Company intends to use the proceeds for resource and exploration field programs, including additional drilling and exploration, feasibility studies, and general working capital.

NVAAF

Reported Earlier, Nova Minerals Raised $2.15M Via Secondary Offering Of 0.43M ADS At $5/ADS

T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) ("T-Mobile") announced today that T-Mobile USA, Inc., its direct wholly-owned subsidiary ("T-Mobile USA" or the "Issuer"), has agreed to sell $700,000,000 aggregate principal amount of its 4.200% Senior Notes due 2029 (the "2029 Notes"), $900,000,000 aggregate principal amount of its 4.700% Senior Notes due 2035 (the "2035 Notes") and $900,000,000 aggregate principal amount of its 5.250% Senior Notes due 2055 (the "2055 Notes," and collectively with the 2029 Notes and the 2035 Notes, the "notes") in a registered public offering.
The offering of the notes is scheduled to close on September 26, 2024, subject to satisfaction of customary closing conditions. T-Mobile USA intends to use the net proceeds from the offering for general corporate purposes, which may include among other things, share repurchases, any dividends declared by T-Mobile's Board of Directors and refinancing of existing indebtedness on an ongoing basis.

TMUS

Reported Earlier, T-Mobile To Raise $2.5B Via Senior Notes Offering

New Mountain Finance Corporation (the "Company," "we," "us" or "our") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMFC#NASDAQ">NMFC</a>) today announced that it has priced an underwritten public offering of $300 million in aggregate principal amount of 6.200% unsecured notes due 2027 (the "Notes").
The Notes will mature on October 15, 2027, and may be redeemed in whole or in part at the Company's option at any time prior to October 15, 2027, at par plus a "make-whole" premium plus accrued interest. The Notes will bear interest at a rate of 6.200% per year payable semi-annually on April 15 and October 15 of each year, beginning April 15, 2025.
The offering is expected to close on September 26, 2024, subject to the satisfaction of customary closing conditions.

NMFC

Reported Earlier, New Mountain Finance Raised $300M Via Secondary Offering Of Unsecured Notes Due 2027

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lnw.com%2F&amp;esheet=54126322&amp;newsitemid=20240923020206&amp;lan=en-US&amp;anchor=Light+%26amp%3B+Wonder%2C+Inc.&amp;index=1&amp;md5=b86e6598104a68d63d8555273b511202">Light &amp; Wonder, Inc.</a> (NASDAQ and ASX: LNW) (together with its subsidiaries "Light &amp; Wonder," "L&amp;W" or the "Company") today received an order from the U.S. District Court for the District of Nevada granting Aristocrat a preliminary injunction relating to L&amp;W's Dragon Train game. We respectfully disagree with the judge's decision and will promptly file an appeal. We will continue to vigorously defend against Aristocrat's claims, including presenting our defenses to a jury at a trial.
Light &amp; Wonder reaffirms its 2025 $1.4 billion Targeted Consolidated AEBITDA(1). We expect continued strong growth across all our businesses. The Company is moving forward on a number of key initiatives to mitigate the immediate impact and any continuing business disruption from today's order. Our pre-ruling estimate of 2025 Consolidated AEBITDA(1) for Dragon Train was less than 5%(2) of the $1.4 billion.
We have a diversified portfolio of successful game franchises that are driving our strong performance and growth, of which Dragon Train is only one. Increased investment in our R&amp;D engine has and continues to deliver innovative, engaging content that gives us a continuing competitive advantage not tied to any one game or franchise.
Light &amp; Wonder has the #1 share(3) and #1 performance position overall for top new sold games and has the top performing game in all 5 for sale categories in North America(4). Additionally, Light &amp; Wonder has 8 of the top 25 premium leased and wide-area progressive parent theme games(4). Our chart-topping game performance continues to be underpinned by our franchises such as ULTIMATE FIRE LINK&#x2122;, INVADERS, our hit Asian-themed games 88 FORTUNES&#xAE; and DANCING DRUMS&#xAE;, stepper favorites QUICK HIT&#x2122; and TRIPLE BLAZING 7s&#x2122;, and Huff N' Puff&#xAE;, where we recently launched a new game extension Huff N' Puff Money Mansion&#xAE; as a leased game. Our market-leading game franchises will continue to drive our Company's strong growth over the long term. We are also already working on new iterations of the Dragon Train franchise consistent with the terms of the Court's ruling.
"We have the best game design talent in the industry, and they are creating great games across all our channels," said Matt Wilson, President and CEO of Light &amp; Wonder. "We are excited about the new games we will be featuring at the Global Gaming Expo in October. We expect our strong growth trajectory to continue, notwithstanding this decision. We have built an amazing business and a solid financial foundation over the last several years with great teams driving our success and are highly confident in our future of continuing innovation and ability to achieve our stated 2025 $1.4 billion Targeted Consolidated AEBITDA(1)."
Our robust capital management strategy remains unchanged. We continue to allocate capital where we can achieve the best shareholder returns, including share repurchases pursuant to our recently approved $1 billion program along with value accretive organic and inorganic investments.

Guidance

Legal

Reported Earlier, Light & Wonder Confirms $1.4B 2025 Consolidated AEBITDA After Court Ruling On Dragon Train Game

BioVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a best efforts public offering of 1,960,800 shares of its common stock (or pre-funded warrants ("Pre-funded Warrants") in lieu thereof) and warrants to purchase up to 1,960,800 shares of common stock at a combined offering price of $1.53 per share (or Pre-funded Warrant) and associated warrant. The warrants will have an exercise price of $1.53 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. The gross proceeds to the Company from the offering are expected to be approximately $3,000,000, before deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes. All of the shares of common stock (or Pre-funded Warrants) and associated warrants are being offered by the Company. The offering is expected to close on September 25, 2024, subject to satisfaction of customary closing conditions. &nbsp;

BIVI

Reported Earlier, BioVie Raised $3M VIa Secondary Stock Offering Of 1.96M Shares At $1.53/Share

InvenTrust Properties Corp. ("InvenTrust" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVT#NYSE">IVT</a>) today announced it has priced an underwritten registered public offering of 8,000,000 shares of its common stock at a price to the public of $28.00 per share for total gross proceeds of $224.0 million. As part of the offering, the Company also granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of the Company's common stock at the public offering price, less the underwriting discount. The offering is expected to close on September 25, 2024 subject to customary closing conditions.
J.P. Morgan, BofA Securities, and Wells Fargo Securities are acting as joint-book-running managers for the public offering. Jefferies and KeyBanc Capital Markets are acting as additional bookrunners for the public offering. BTIG and Fifth Third Securities are acting as co-managers for the public offering.
The Company intends to use the net proceeds for general corporate purposes, including, but not limited to, funding the acquisition of additional properties, repayment of short-term and long-term indebtedness (including mortgage loans, including a $72.5 million loan with Bank of America, N.A, and amounts outstanding from time to time under the Company's revolving credit facility) and providing for working capital.

Reported Earlier, InvenTrust Properties Raised $224M Via Upsized Secondary Stock Offering Of 8M Shares (Prior $6.5M Shares) At $28/Share

Hawaiian Electric Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) ("HEI" or the "Company") today announced that it has priced its previously announced public offering of 54,054,054 shares of its common stock at a price of $9.25 per share. The offering is expected to close on September 25, 2024, subject to customary closing conditions.
The Company has granted the underwriters of the offering an option to purchase up to an additional 8,108,108 shares of common stock at the public offering price less underwriting discounts and commissions.
HEI intends to use the net proceeds from the offering to fund its contribution to the expected Maui wildfire tort litigation settlement and for general corporate purposes.

Hawaiian Electric Industries Raised $500M Via Secondary Stock Offering Of 54M Shares At $9.25/Share

<a href="https://www.globenewswire.com/Tracker?data=QOxRsnrI4lIcPvAJOHMkqpD2ZCcXLqncOnt8jZtYl5Orntqk98Ug6cXUt26iWYSQ">UCB</a> (Euronext Brussels: UCB) and <a href="https://www.globenewswire.com/Tracker?data=dQmAuZ_6afdr57GCMIz_bBuykaXWwgeC4T9F0-q_hAYdmPT_oUGMDy50CId7wM1j4bYykSMNSRmZ3zuqKQjiUA==">Biogen Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) today announced positive topline results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate, in people living with moderate-to-severe systemic lupus erythematosus (SLE). Dapirolizumab pegol, in addition to standard-of-care (SOC) treatment, met the primary endpoint to demonstrate greater improvement of moderate-to-severe disease activity as assessed by achievement of British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) after 48 weeks versus placebo in addition to SOC. Clinical improvements were observed among key secondary endpoints measuring disease activity and flares.
The safety profile of dapirolizumab pegol was generally consistent with previous studies and with that expected in study participants with systemic lupus erythematosus receiving an immunomodulator.
"These positive results with dapirolizumab pegol represent encouraging progress in the development of medicines that can improve the lives of those living with lupus, an area that remains one of high unmet medical need and where women are disproportionately affected," said Fiona du Monceau, Head of Patient Evidence at UCB. "We have confidence in the unique mode of action of dapirolizumab pegol which targets multiple inflammatory pathways involved in the pathogenesis of SLE. As we pursue the next steps in the clinical development of this potentially differentiated treatment, we extend our appreciation to the patients, study investigators and the clinical community for their ongoing support and participation in this important research."
Based on the successful outcome of the PHOENYCS GO study, UCB and Biogen are initiating a second Phase 3 trial of dapirolizumab pegol in 2024, PHOENYCS FLY. Participants from the PHOENYCS GO study will continue to be followed in a long-term open-label study.
"Our hypothesis is that impacting the CD40L pathway, a central mechanism in immune response, would translate to significant impact on SLE disease burden. These results demonstrate that dapirolizumab pegol has the promise to provide meaningful benefit in this serious, chronic, and often devastating disease," said Diana Gallagher, MD, Head of AD, MS and Immunology Development Units at Biogen. "We are committed to delivering new treatment options for this autoimmune disease and believe the overall efficacy and safety seen in PHOENYCS GO support further development of dapirolizumab pegol in SLE."
PHOENYCS GO (n= 321) is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study of dapirolizumab pegol as an add on therapy to standard of care compared to placebo with standard of care. The primary outcome measure was improvement of moderate-to-severe disease activity at Week 48 using BICLA, an established, composite primary efficacy endpoint for measurement of clinical disease activity based on patient medical history, clinical examination and laboratory tests.
Detailed results from the PHOENYCS GO study will be presented at an upcoming medical congress.

BIIB

UCB And Biogen Report Results In Phase 3 Lupus Drug Trial

CRH plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRH#NYSE">CRH</a>), the leading provider of building materials solutions, announces that Albert Manifold has decided to retire as Chief Executive Officer at the end of 2024 and that he is to be succeeded by Jim Mintern.
&nbsp;
Mr. Mintern is currently CRH's Chief Financial Officer and has been a director of its board since June 2021. He has over 30 years of experience in the building materials industry and 22 years with CRH, serving in various senior leadership roles. Mr. Mintern has deep industry knowledge, has led a variety of operational businesses, and is an accomplished developer of teams and people. He also has extensive portfolio management, financial and capital markets expertise. Most recently, Mr. Mintern led the strategic transition of CRH's primary listing to the New York Stock Exchange.
Mr. Manifold has held varied responsibilities with CRH since he joined in 1998. He was appointed Chief Executive Officer in January 2014. Mr. Manifold will step down from the board and relinquish his executive responsibilities on December 31, 2024. He will continue as an advisor to CRH for a further 12 months.
&nbsp;

Management

CRH Names CFO Jim Mintern As CEO, Effective 2024 End, Succeeding Albert Manifold

As Tesla Stock Sneaks Into Positive Territory For Year Fund Manager Says Not 10/10 Robotaxi Event But This Would Strengthen Fledgling Recovery (alt HL)
Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) <a href="https://www.benzinga.com/news/24/09/40992274/what-happened-with-tesla-stock-today">shares climbed nearly 5% Monday</a> and settled at a psychological resistance of $250, with optimism concerning third-quarter deliveries outperformance fueling much of the upside. Amid the stock surge, a fund manager weighed in on the potential impact of the upcoming Oct. 10 Robotaxi launch event on the stock.
10/10 Stock Mover? Future Fund LLC Managing Partner Gary Black is not convinced that Oct. 10 would be a catalyst for the stock, although he didn&#8217;t rule the possibility out. He said his apprehension stemmed from the fact that Tesla&#8217;s full self-driving technology is not yet close to the 99.99% efficacy needed for unsupervised autonomy.
Most analysts have discounted supervised FSD in their models, assuming a 15-20% take rate for the existing fleet and current deliveries. Also, analysts have assumed that supervised FSD with 97% efficacy will sell more Teslas, he added.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Many <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a> bulls keep talking about the robotaxi event on 10/10 as a catalyst for TSLA stock. It may be. TSLA FSD is not yet close to the 99.99% efficacy needed for unsupervised autonomy. Supervised FSD is already in most analysts' models at a 15-20% take rate x the existing… <a href="https://t.co/PFVs6IWZtz">pic.twitter.com/PFVs6IWZtz</a>
&mdash; Gary Black (@garyblack00) <a href="https://twitter.com/garyblack00/status/1838261891912572954?ref_src=twsrc%5Etfw">September 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/money/how-to-buy-tesla-stock">How To Buy Tesla (TSLA) Stock</a>
Upbeat On Low-End Model: Black reiterated his optimism regarding the $25,000-$30,000 compact car from Tesla&#8217;s stable. The optimism is premised on what happened in 2019-2020 to the fundamentals and the stock after the Model Y launch, he said.
The Model Y was launched in 2019 amid shorts&#8217; high skepticism but the vehicle &#8220;ushered in a whole new TAM by vaulting TSLA into the fast-growing CUV category,&#8221; he added.
The fund manager said that the launch of a sub-$30K car on Oct. 10 is not very certain, but if it does, that&#8217;s more of a reason to buy the stock. He said that an affordable electric vehicle will allow Tesla to leverage its brand, higher range, superior tech, and better performance in the large compact category, where Toyota Motor Corp.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>) Corolla is the leader.
&#8220;Similar to 2019-2020, $TSLAQ shorts don't understand the incremental TAM math where most TSLA Compact volume will be incremental, and not cannibalized from Model 3, which competes in an entirely different category (affordable sedans),&#8221; Black said.
Although <a href="https://www.benzinga.com/quote/TSLA/short-interest">Tesla&#8217;s short interest is far lower </a>currently compared to 2019-2020, the likely change in the current trajectory of earnings estimates from very negative to positive will change the Tesla investment narrative, the Tesla bull said. He sees Tesla&#8217;s volumes rising again, driving earnings estimates higher, which in turn will propel the stock price higher.
Tesla ended Monday&#8217;s session up 4.93% to $250, according to <a href="https://benzinga.grsm.io/register174">Benzinga Pro data.</a> With the recent rally, the stock has turned to black for the year and is up 0.61%.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="http://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40932786/tesla-bull-explains-why-elon-musks-xai-is-critical-to-ev-makers-autonomous-ambition">Tesla Bull Explains Why Elon Musk&#8217;s xAI Is Critical To EV Maker&#8217;s Autonomous Ambitions</a></li>
</ul>
Image via Shutterstock

Analyst Color

TSLA

Tesla Bull Dampens Enthusiasm Regarding 10/10 Robotaxi Event But Here's What Would Take To Strengthen Fledgling Stock Recovery

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) senior executive Ashok Elluswamy on Monday hinted that the company is rushing to deploy its full self-driving (FSD) driver assistance technology on Cybertrucks, with a GIF from the 1980 movie &#8220;Airplane!&#8221;
What Happened: Tesla said earlier this month that FSD will be deployed on the <a href="https://www.benzinga.com/news/24/09/40724069/tesla-fsd-rollout-in-china-europe-planned-for-q1-2025">Cybertruck this month with other improvements</a> in the software. 
&#8220;Waiting,&#8221; Tesla wrote on its official account dedicated to Cybertruck updates on Monday. 
Elluwamy responded with a gif from &#8216;Airplane!&#8217; showing Robert Hays, who acted as the protagonist of the film, sweating through as he struggles to land a plane and implying that the team is hard at work to deploy the technology on the stainless steel truck.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"> <a href="https://t.co/MFYDKKLUPk">pic.twitter.com/MFYDKKLUPk</a>
&mdash; Ashok Elluswamy (@aelluswamy) <a href="https://twitter.com/aelluswamy/status/1838338402997223861?ref_src=twsrc%5Etfw">September 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Tesla CEO Elon Musk and Cybertruck lead engineer Wes Morrill also responded humorously to Elluswamy. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f602;
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1838351437694173364?ref_src=twsrc%5Etfw">September 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">driving lastest build tonight <a href="https://t.co/iZr8WNl3Pu">pic.twitter.com/iZr8WNl3Pu</a>
&mdash; Wes (@wmorrill3) <a href="https://twitter.com/wmorrill3/status/1838387591521116303?ref_src=twsrc%5Etfw">September 24, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Tesla deployed <a href="https://www.benzinga.com/news/24/09/40791286/tesla-ceo-elon-musk-considers-making-steering-yoke-stationary-while-cybertruck-parks-itself">parking assistance features</a> on the Cybertruck and actually smart summon feature on other Tesla vehicles this month as part of its plans to enhance the capability of the FSD software to eventually drive autonomously without driver supervision.
However, FSD is yet to be deployed on the Cybertruck as of date.
Tesla is known for delaying its provided timelines. Musk has been saying for years that Tesla vehicles will be able to drive autonomously but FSD software still requires active driver supervision. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40979752/elon-musk-says-buses-wont-be-needed-once-tesla-robotaxis-start-operating-will-take-people-point-" target="_blank" rel="noreferrer noopener">Elon Musk Says Buses Won&#8217;t Be Needed Once Tesla Robotaxis Start Operating: &#8216;Will Take People Point To Point For A Similar Cost&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

Tesla Team Working Hard At Deploying FSD On Cybertruck, Senior Exec Implies

CNS Pharmaceuticals announces pricing of registered direct offering and concurrent private placement

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Thursday and we have breakdowns of all the latest news sending shares higher and lower this morning!



Moving stocks this morning are share sales, a new order, a closed public offering and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Blue Star Foods (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsfc-stock-quote/">BSFC</a>) stock is rocketing more than 67% alongside heavy pre-market trading.</li>



<li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) shares are surging over 67% after UBS Group AG (NYSE:<a href="https://investorplace.com/stock-quotes/ubs-stock-quote/">UBS</a>) <a href="https://www.benzinga.com/news/24/07/39725326/ev-maker-volcons-stock-skyrockets-over-70-in-pre-market-following-ubs-groups-buy-sell-transactions">bought and sold shares</a>.</li>



<li>CNS Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cnsp-stock-quote/">CNSP</a>) stock is soaring more than 51% alongside strong early morning trading.</li>



<li>MingZhu Logistics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ygmz-stock-quote/">YGMZ</a>) shares are gaining over 42% with strong pre-market trading today.</li>



<li>Actelis Networks (NASDAQ:<a href="https://investorplace.com/stock-quotes/asns-stock-quote/">ASNS</a>) stock is heading more than 30% higher on a <a href="https://www.nasdaq.com/press-release/actelis-receives-260000-order-major-mid-atlantic-us-county-traffic-system">traffic system order</a>.</li>



<li>Phoenix Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/pev-stock-quote/">PEV</a>) shares are increasing over 18% despite a lack of news this morning.</li>



<li>Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) stock is climbing more than 17% as it <a href="https://investorplace.com/2024/07/why-is-kazia-therapeutics-kzia-stock-up-300-today/">continues a recent rally</a>.</li>



<li>Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) shares are rising close to 16% with heavy early morning trading.</li>



<li>Staffing 360 Solutions (NASDAQ:<a href="https://investorplace.com/stock-quotes/staf-stock-quote/">STAF</a>) stock is jumping over 13% on Thursday without any clear news.</li>



<li>Naas Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/naas-stock-quote/">NAAS</a>) shares are up 13% as part of an ongoing rally.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>TuanChe (NASDAQ:<a href="https://investorplace.com/stock-quotes/tc-stock-quote/">TC</a>) stock is plummeting more than 33% without any apparent news this morning.</li>



<li>Warrantee (NASDAQ:<a href="https://investorplace.com/stock-quotes/wrnt-stock-quote/">WRNT</a>) shares are diving over 27% on Thursday.</li>



<li>Inspire Veterinary (NASDAQ:<a href="https://investorplace.com/stock-quotes/ivp-stock-quote/">IVP</a>) stock is tumbling more than 26% after <a href="https://www.nasdaq.com/press-release/inspire-veterinary-partners-announces-closing-6-million-public-offering-2024-07-10">closing a public offering</a>.</li>



<li>Quhuo (NASDAQ:<a href="https://investorplace.com/stock-quotes/qh-stock-quote/">QH</a>) shares are taking an over 19% beating after a recent rally.</li>



<li>Cingulate (NASDAQ:<a href="https://investorplace.com/stock-quotes/cing-stock-quote/">CING</a>) stock is sliding more than 18% following a surprise rally yesterday.</li>



<li>Next Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxtt-stock-quote/">NXTT</a>) shares are dropping over 16% on Thursday morning.</li>



<li>Janover (NASDAQ:<a href="https://investorplace.com/stock-quotes/jnvr-stock-quote/">JNVR</a>) stock is decreasing more than 15% <a href="https://www.nasdaq.com/press-release/janovers-new-insurtech-platform-launches-do-liability-insurance-publicly-traded">after climbing higher yesterday</a>.</li>



<li>Zapp Electric Vehicles (NASDAQ:<a href="https://investorplace.com/stock-quotes/zapp-stock-quote/">ZAPP</a>) shares are slipping over 14% as it <a href="https://investorplace.com/2024/07/why-is-zapp-electric-vehicles-zapp-stock-down-25-today/">continues to retreat</a>.</li>



<li>Telesis Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/tbio-stock-quote/">TBIO</a>) stock is dipping nearly 14% after a similar rise yesterday.</li>



<li>SAI.TECH Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/sai-stock-quote/">SAI</a>) shares close out our pre-market stock movers down more than 13% <a href="https://www.nasdaq.com/press-release/saitech-announces-mou-signings-heatnuc-targeting-nuclear-and-smr-markets-middle-east">following a rally yesterday</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-july-11th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

CNS Pharmaceutical files for 2.36M offering of common stock

An update from CNS Pharmaceuticals (CNSP) is now available. CNS Pharmaceuticals, Inc. has secured an exclusive license from Cortice Biosciences, In...

CNS Pharmaceuticals Expands Portfolio with Strategic Licensing Deal

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
CNS Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cnsp-stock-quote/">CNSP</a>) stock is heading lower on Tuesday after the clinical-pharmaceutical company <a href="https://finance.yahoo.com/news/cns-pharmaceuticals-expands-pipeline-license-110000505.html">announced an expansion to its pipeline</a>.



CNS Pharmaceuticals has acquired an exclusive license and the intellectual property rights to TPI 287. This is a potential blood-brain barrier permeable microtubule inhibitor in development to treat Glioblastoma.



John Climaco, CEO of CNS Pharmaceuticals, said the following about the news.




&ldquo;For years, our team has searched for another drug candidate with the same high level of human data-supported therapeutic potential in GBM as Berubicin. The in-licensing of TPI 287 is a transformational step forward and we are prepared for the next stage to execute our vision of CNS Pharmaceuticals being the leading biopharma company developing drugs for this devastating and currently inescapably fatal disease.&rdquo;




<h2>Why This Affects CNSP Stock</h2>



The surprising news here is how the company acquired the license and rights. Rather than paying for them with cash, the company issued 616,698 shares of CNSP stock to cover the deal. It issued these shares to TPI 287 maker Cortice.



Investors aren&rsquo;t pleased about this news with it dropping shares of CNSP stock by 69.2% as of Tuesday afternoon. The stock is also down 99.5% since the start of the year.



There are even more stock market stories traders are going to want to read about today!



We have all of that ready with our dive into the latest stock market news on Tuesday! Among that is Georgia Rep. Marjorie Taylor Greene stock buys, the latest on 2U&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/twou-stock-quote/">TWOU</a>) stock&nbsp;and more. All of this info is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/marjorie-taylor-greene-doubles-down-on-ai-boom-with-new-buys/">Marjorie Taylor Greene Doubles Down on AI Boom With New Buys</a></li>



<li><a href="https://investorplace.com/2024/07/2u-twou-stock-continues-to-surge-in-bankruptcy-rally/">2U (TWOU) Stock Continues to Surge in Bankruptcy Rally</a></li>



<li><a href="https://investorplace.com/2024/07/a-potential-stock-market-crash-trigger-looms-on-july-31/">A Potential Stock Market Crash Trigger Looms on July 31</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-cns-pharmaceuticals-cnsp-stock-down-69-today/">Why Is CNS Pharmaceuticals (CNSP) Stock Down 69% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is CNS Pharmaceuticals (CNSP) Stock Down 69% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
A Microsoft (NASDAQ:<a href="https://investorplace.com/stock-quotes/msft-stock-quote/">MSFT</a>) Office outage has workers annoyed as its causing problems with them being able to use the company&rsquo;s services.



This newest outage is affecting Microsoft Office and the company&rsquo;s <a href="https://x.com/MSFT365Status/status/1818267438435147865">Microsoft 365 services and features</a>. The company is working to resolve these issues and is advising users to track the outage status from the admin center.



Unfortunately, many users on X are reporting that they can&rsquo;t even access the admin center due to the outage. That resulted in Microsoft&rsquo;s Azure Services support account chiming in. It noted that there are also issues with its service that may be hindering users.



Here&rsquo;s what Mircosoft said about the problems in a post on X.




&ldquo;We&rsquo;ve applied mitigations and rerouted user requests to provide relief. We&rsquo;re monitoring the service to confirm resolution and further information can be found at <a href="https://status.cloud.microsoft" title="https://status.cloud.microsoft">https://status.cloud.microsoft</a> or under MO842351 in the admin center.&rdquo;




<h2>Microsoft Office Outage: What Happens Next?</h2>



It looks like the problems are clearly on Microsoft&rsquo;s end. That means there&rsquo;s not much users can do until the company sorts the matter out. Those looking for further updates can find them under the MO842351 ticker in the admin center, so long as they can get to it with the ongoing outage.



It&rsquo;s also worth noting that this comes not too long after <a href="https://www.bloomberg.com/news/articles/2024-07-30/microsoft-reports-outage-of-office-applications-and-services?embedded-checkout=true">another outage affected Windows computers</a>. Granted, that one was the fault of CrowdStrike (NASDAQ:<a href="https://investorplace.com/stock-quotes/crwd-stock-quote/">CRWD</a>) pushing out a bad update to users of Microsoft&rsquo;s operating system.



Investors looking for more of the biggest stock market stories today are in luck!



We have all of the hottest stock market news traders need to know about on Tuesday! That includes everything happening with Cassava Sciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sava-stock-quote/">SAVA</a>), SoundHound AI&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/soun-stock-quote/">SOUN</a>) and CNS Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/cnsp-stock-quote/">CNSP</a>) stock today. All of that info is ready to go at the links below!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/sava-stock-cassava-sciences-extends-simufilam-trials-as-much-as-36-months/">SAVA Stock: Cassava Sciences Extends Simufilam Trials as Much as 36 Months</a></li>



<li><a href="https://investorplace.com/2024/07/soun-stock-alert-soundhound-expands-ai-rollout-with-stellantis/">SOUN Stock Alert: SoundHound Expands AI Rollout with Stellantis</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-cns-pharmaceuticals-cnsp-stock-down-69-today/">Why Is CNS Pharmaceuticals (CNSP) Stock Down 69% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/microsoft-office-outage-microsoft-investigates-applications-services-issue/">Microsoft Office Outage: Microsoft Investigates Applications, Services Issue</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Microsoft Office Outage: Microsoft Investigates Applications, Services Issue

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
SoundHound AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/soun-stock-quote/">SOUN</a>) stock is in the news Tuesday as the company is expanding its artificial intelligence (<a href="https://investorplace.com/stock-quotes/ai-stock-quote/">AI</a>) rollout <a href="https://finance.yahoo.com/news/soundhound-ai-rolls-voice-assistant-130300356.html">via a deal</a> with Stellantis (NYSE:<a href="https://investorplace.com/stock-quotes/stla-stock-quote/">STLA</a>).



With this collaboration, Alfa Romeo and Citro&euml;n will start adopting SoundHound AI&rsquo;s voice assistant. This includes vehicles sold in several European markets. The company&rsquo;s AI assistant is powered by ChatGPT.



SoundHound AI notes that with this integration, users will get live assistance while driving their vehicles. That includes the ability to ask for directions, popular nearby attractions and more.



Michael Zagorsek, COO of SoundHound AI, said the following about the news.




&ldquo;Drivers are still uncovering new and exciting uses for this highly capable, AI-driven voice technology. As we enter a new era for the vehicle cockpit, SoundHound is constantly pushing to deliver elite products that automakers trust and drivers love.&rdquo;




<h2>What This Does for SOUN Stock Today</h2>



SOUN stock is getting a 1.3% boost on Tuesday alongside this news. That has more than 13 million shares traded, as compared to a daily average of about 26.3 million units. Investors will also note that SOUN shares are up 132.8% since the start of the year.



We have all of the biggest stock market stories that traders are going to want to read about today!



That includes our coverage of all the latest stock market news available on Tuesday! A few examples of that is what&rsquo;s happening with shares of CNS Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/cnsp-stock-quote/">CNSP</a>) stock, Georgia Rep. Marjorie Taylor Greene stock buys and why 2U&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/twou-stock-quote/">TWOU</a>) stock is up today. All of this news is good to go at the links below!



<h2>More Tuesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-cns-pharmaceuticals-cnsp-stock-down-69-today/">Why Is CNS Pharmaceuticals (CNSP) Stock Down 69% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/marjorie-taylor-greene-doubles-down-on-ai-boom-with-new-buys/">Marjorie Taylor Greene Doubles Down on AI Boom With New Buys</a></li>



<li><a href="https://investorplace.com/2024/07/2u-twou-stock-continues-to-surge-in-bankruptcy-rally/">2U (TWOU) Stock Continues to Surge in Bankruptcy Rally</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/soun-stock-alert-soundhound-expands-ai-rollout-with-stellantis/">SOUN Stock Alert: SoundHound Expands AI Rollout with Stellantis</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SOUN Stock Alert: SoundHound Expands AI Rollout with Stellantis

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
CNS Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cnsp-stock-quote/">CNSP</a>) just reported results for the second quarter of 2024.<ul><li>CNS Pharmaceuticals reported earnings per share of -$6.72.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cnsp-stock-earnings-cns-pharmaceuticals-for-q2-of-2024/">CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q2 2024

CNS Pharmaceuticals reports Q2 results

CNS Pharmaceuticals regains Nasdaq compliance

ASNS

BSFC

CING

JNVR

KZIA

MSFT

NAAS

NXTT

SAVA

SLRX

SOUN

STAF

STLA

TBIO

VLCN

WRNT

YGMZ

ZAPP

Screenshot 2024-02-26 at 8.44.39 PM

Biotech

GBM, One Of The Deadliest Cancers, Could Have New Hope With Novel Drug

Events

Press Releases

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

CNS Pharma

CNS Pharma (CNSP) Forecast

CNS Pharma (NASDAQ:CNSP) Stock, Quote.Headers.trade-ideas